# A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Study · id `cardio:ct-nct03730662` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03730662](<https://clinicaltrials.gov/study/NCT03730662>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03730662

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2002 participants.

## Technical summary

Registry record NCT03730662. Randomized; no masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2021-01-22 (actual). Results posted on 2022-02-14.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2002 participants (enrolled count; ClinicalTrials.gov record NCT03730662, source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)
- Started: 2018-11-20 (actual) (ClinicalTrials.gov record NCT03730662, source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)
- Primary completion: 2021-01-22 (actual) (ClinicalTrials.gov record NCT03730662, source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)
- Completion: 2021-04-22 (actual) (ClinicalTrials.gov record NCT03730662, source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)
- Results first posted: 2022-02-14 (ClinicalTrials.gov record NCT03730662, source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Canada; Greece; Israel; Mexico; Poland; Puerto Rico; Romania; Russia; Slovakia; Spain; Taiwan (ClinicalTrials.gov record NCT03730662, source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03730662-2022-02-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
- Acronym: SURPASS-4
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (`cardio:pubmed-34672967`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial (`cardio:pubmed-36152639`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 15b87af8fe3d30cab4a71084121eefc2647ff2e236e2e3eefed2cc80e86a2ceb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
